Global Endocrinology Drugs

Endocrinology Drugs Comprehensive Study by Type (Diabetic Aagents, Hormone Agonists, Hormone Antagonists), Drug (Prescription Drugs, Over-the-counter Drugs), End User (Hospitals, Commercial Laboratories, Ambulatory Care Centres, Others) Players and Region - Global Market Outlook to 2030

Endocrinology Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Endocrinology Drugs
The global market of endocrinology drugs market has been witnessing a remarkable upsurge due to rising in the prevalence of various hormone-related medical conditions, such as hypogonadism, diabetes, hyperthyroidism, and hypothyroidism, in its overall size and valuation. Since the incidence rate of diabetes is exceptionally high across the world, fueled by an unhealthy diet and the reducing involvement of consumers in physical activities, the global endocrinology drugs market is likely has led to significant a high-paced rise in the forecast period.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Endocrinology Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novo Nordisk (Denmark), Merck & Co., Inc. (United States), Sanofi (France), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Eli Lily (United States), AbbVie Inc. (United States), HanAll BioPharma (South Korea), Bayer HealthCare Pharmaceuticals (Germany), Acerus Pharmaceuticals (Canada) and BHV Pharma (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Acrux DDS (Australia), Biocon (India), Hanmi Pharmaceutical (South Korea), MannKind (United States), Precigen, Inc (United States), ChipScreen Biosciences (China), Endo Pharmaceuticals (Ireland) and Takeda Pharmaceuticals (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Endocrinology Drugs market by Type (Diabetic Aagents, Hormone Agonists and Hormone Antagonists) and Region.



On the basis of geography, the market of Endocrinology Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug, the sub-segment i.e. Prescription Drugs will boost the Endocrinology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Endocrinology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
High Prevalence of Diabetes

Market Growth Drivers:
Increasing Number of Cases of Hypogonadism in Men and Growing Incidence Rate of Diabetes is Exceptionally High across the Globe

Challenges:
Intense Competition Among the Competitors

Restraints:
Strict Government Rules and Regulations

Opportunities:
Increasing Awareness among People Pertaining to Thyroid, Diabetes, and other Hormone-Related Disorders

Market Leaders and their expansionary development strategies
On 4th August 2020, Merck and Hanmi Pharmaceutical have announced that the companies have entered into an exclusive licensing agreement for the development, manufacture, and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis (NASH).
On 29th December 2020, Novo Nordisk has announced the submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisation for Ozempic, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults.


Key Target Audience
Endocrinology Drugs Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Diabetic Aagents
  • Hormone Agonists
  • Hormone Antagonists
By Drug
  • Prescription Drugs
  • Over-the-counter Drugs

By End User
  • Hospitals
  • Commercial Laboratories
  • Ambulatory Care Centres
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Cases of Hypogonadism in Men
      • 3.2.2. Growing Incidence Rate of Diabetes is Exceptionally High across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Intense Competition Among the Competitors
    • 3.4. Market Trends
      • 3.4.1. High Prevalence of Diabetes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Endocrinology Drugs, by Type, Drug, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Endocrinology Drugs (Value)
      • 5.2.1. Global Endocrinology Drugs by: Type (Value)
        • 5.2.1.1. Diabetic Aagents
        • 5.2.1.2. Hormone Agonists
        • 5.2.1.3. Hormone Antagonists
      • 5.2.2. Global Endocrinology Drugs by: Drug (Value)
        • 5.2.2.1. Prescription Drugs
        • 5.2.2.2. Over-the-counter Drugs
      • 5.2.3. Global Endocrinology Drugs by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Commercial Laboratories
        • 5.2.3.3. Ambulatory Care Centres
        • 5.2.3.4. Others
      • 5.2.4. Global Endocrinology Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Endocrinology Drugs (Volume)
      • 5.3.1. Global Endocrinology Drugs by: Type (Volume)
        • 5.3.1.1. Diabetic Aagents
        • 5.3.1.2. Hormone Agonists
        • 5.3.1.3. Hormone Antagonists
      • 5.3.2. Global Endocrinology Drugs by: Drug (Volume)
        • 5.3.2.1. Prescription Drugs
        • 5.3.2.2. Over-the-counter Drugs
      • 5.3.3. Global Endocrinology Drugs by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Commercial Laboratories
        • 5.3.3.3. Ambulatory Care Centres
        • 5.3.3.4. Others
      • 5.3.4. Global Endocrinology Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Endocrinology Drugs (Price)
      • 5.4.1. Global Endocrinology Drugs by: Type (Price)
  • 6. Endocrinology Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novo Nordisk (Denmark)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lily (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AbbVie Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. HanAll BioPharma (South Korea)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer HealthCare Pharmaceuticals (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Acerus Pharmaceuticals (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. BHV Pharma (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Endocrinology Drugs Sale, by Type, Drug, End User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Endocrinology Drugs (Value)
      • 7.2.1. Global Endocrinology Drugs by: Type (Value)
        • 7.2.1.1. Diabetic Aagents
        • 7.2.1.2. Hormone Agonists
        • 7.2.1.3. Hormone Antagonists
      • 7.2.2. Global Endocrinology Drugs by: Drug (Value)
        • 7.2.2.1. Prescription Drugs
        • 7.2.2.2. Over-the-counter Drugs
      • 7.2.3. Global Endocrinology Drugs by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Commercial Laboratories
        • 7.2.3.3. Ambulatory Care Centres
        • 7.2.3.4. Others
      • 7.2.4. Global Endocrinology Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Endocrinology Drugs (Volume)
      • 7.3.1. Global Endocrinology Drugs by: Type (Volume)
        • 7.3.1.1. Diabetic Aagents
        • 7.3.1.2. Hormone Agonists
        • 7.3.1.3. Hormone Antagonists
      • 7.3.2. Global Endocrinology Drugs by: Drug (Volume)
        • 7.3.2.1. Prescription Drugs
        • 7.3.2.2. Over-the-counter Drugs
      • 7.3.3. Global Endocrinology Drugs by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Commercial Laboratories
        • 7.3.3.3. Ambulatory Care Centres
        • 7.3.3.4. Others
      • 7.3.4. Global Endocrinology Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Endocrinology Drugs (Price)
      • 7.4.1. Global Endocrinology Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Endocrinology Drugs: by Type(USD Million)
  • Table 2. Endocrinology Drugs Diabetic Aagents , by Region USD Million (2018-2023)
  • Table 3. Endocrinology Drugs Hormone Agonists , by Region USD Million (2018-2023)
  • Table 4. Endocrinology Drugs Hormone Antagonists , by Region USD Million (2018-2023)
  • Table 5. Endocrinology Drugs: by Drug(USD Million)
  • Table 6. Endocrinology Drugs Prescription Drugs , by Region USD Million (2018-2023)
  • Table 7. Endocrinology Drugs Over-the-counter Drugs , by Region USD Million (2018-2023)
  • Table 8. Endocrinology Drugs: by End User(USD Million)
  • Table 9. Endocrinology Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 10. Endocrinology Drugs Commercial Laboratories , by Region USD Million (2018-2023)
  • Table 11. Endocrinology Drugs Ambulatory Care Centres , by Region USD Million (2018-2023)
  • Table 12. Endocrinology Drugs Others , by Region USD Million (2018-2023)
  • Table 13. South America Endocrinology Drugs, by Country USD Million (2018-2023)
  • Table 14. South America Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 15. South America Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 16. South America Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 17. Brazil Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 18. Brazil Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 19. Brazil Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 20. Argentina Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 21. Argentina Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 22. Argentina Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 23. Rest of South America Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 24. Rest of South America Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 25. Rest of South America Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 26. Asia Pacific Endocrinology Drugs, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 28. Asia Pacific Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 29. Asia Pacific Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 30. China Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 31. China Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 32. China Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 33. Japan Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 34. Japan Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 35. Japan Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 36. India Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 37. India Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 38. India Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 39. South Korea Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 40. South Korea Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 41. South Korea Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 42. Taiwan Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 43. Taiwan Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 44. Taiwan Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 45. Australia Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 46. Australia Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 47. Australia Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 51. Europe Endocrinology Drugs, by Country USD Million (2018-2023)
  • Table 52. Europe Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 53. Europe Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 54. Europe Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 55. Germany Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 56. Germany Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 57. Germany Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 58. France Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 59. France Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 60. France Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 61. Italy Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 62. Italy Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 63. Italy Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 64. United Kingdom Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 65. United Kingdom Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 66. United Kingdom Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 67. Netherlands Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 68. Netherlands Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 69. Netherlands Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 70. Rest of Europe Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 71. Rest of Europe Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 72. Rest of Europe Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 73. MEA Endocrinology Drugs, by Country USD Million (2018-2023)
  • Table 74. MEA Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 75. MEA Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 76. MEA Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 77. Middle East Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 78. Middle East Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 79. Middle East Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 80. Africa Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 81. Africa Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 82. Africa Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 83. North America Endocrinology Drugs, by Country USD Million (2018-2023)
  • Table 84. North America Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 85. North America Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 86. North America Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 87. United States Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 88. United States Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 89. United States Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 90. Canada Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 91. Canada Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 92. Canada Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 93. Mexico Endocrinology Drugs, by Type USD Million (2018-2023)
  • Table 94. Mexico Endocrinology Drugs, by Drug USD Million (2018-2023)
  • Table 95. Mexico Endocrinology Drugs, by End User USD Million (2018-2023)
  • Table 96. Endocrinology Drugs Sales: by Type(KG)
  • Table 97. Endocrinology Drugs Sales Diabetic Aagents , by Region KG (2018-2023)
  • Table 98. Endocrinology Drugs Sales Hormone Agonists , by Region KG (2018-2023)
  • Table 99. Endocrinology Drugs Sales Hormone Antagonists , by Region KG (2018-2023)
  • Table 100. Endocrinology Drugs Sales: by Drug(KG)
  • Table 101. Endocrinology Drugs Sales Prescription Drugs , by Region KG (2018-2023)
  • Table 102. Endocrinology Drugs Sales Over-the-counter Drugs , by Region KG (2018-2023)
  • Table 103. Endocrinology Drugs Sales: by End User(KG)
  • Table 104. Endocrinology Drugs Sales Hospitals , by Region KG (2018-2023)
  • Table 105. Endocrinology Drugs Sales Commercial Laboratories , by Region KG (2018-2023)
  • Table 106. Endocrinology Drugs Sales Ambulatory Care Centres , by Region KG (2018-2023)
  • Table 107. Endocrinology Drugs Sales Others , by Region KG (2018-2023)
  • Table 108. South America Endocrinology Drugs Sales, by Country KG (2018-2023)
  • Table 109. South America Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 110. South America Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 111. South America Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 112. Brazil Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 113. Brazil Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 114. Brazil Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 115. Argentina Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 116. Argentina Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 117. Argentina Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 118. Rest of South America Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 119. Rest of South America Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 120. Rest of South America Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 121. Asia Pacific Endocrinology Drugs Sales, by Country KG (2018-2023)
  • Table 122. Asia Pacific Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 123. Asia Pacific Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 124. Asia Pacific Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 125. China Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 126. China Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 127. China Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 128. Japan Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 129. Japan Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 130. Japan Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 131. India Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 132. India Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 133. India Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 134. South Korea Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 135. South Korea Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 136. South Korea Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 137. Taiwan Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 138. Taiwan Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 139. Taiwan Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 140. Australia Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 141. Australia Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 142. Australia Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 143. Rest of Asia-Pacific Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 144. Rest of Asia-Pacific Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 145. Rest of Asia-Pacific Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 146. Europe Endocrinology Drugs Sales, by Country KG (2018-2023)
  • Table 147. Europe Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 148. Europe Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 149. Europe Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 150. Germany Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 151. Germany Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 152. Germany Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 153. France Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 154. France Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 155. France Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 156. Italy Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 157. Italy Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 158. Italy Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 159. United Kingdom Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 160. United Kingdom Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 161. United Kingdom Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 162. Netherlands Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 163. Netherlands Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 164. Netherlands Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 165. Rest of Europe Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 166. Rest of Europe Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 167. Rest of Europe Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 168. MEA Endocrinology Drugs Sales, by Country KG (2018-2023)
  • Table 169. MEA Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 170. MEA Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 171. MEA Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 172. Middle East Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 173. Middle East Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 174. Middle East Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 175. Africa Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 176. Africa Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 177. Africa Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 178. North America Endocrinology Drugs Sales, by Country KG (2018-2023)
  • Table 179. North America Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 180. North America Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 181. North America Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 182. United States Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 183. United States Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 184. United States Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 185. Canada Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 186. Canada Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 187. Canada Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 188. Mexico Endocrinology Drugs Sales, by Type KG (2018-2023)
  • Table 189. Mexico Endocrinology Drugs Sales, by Drug KG (2018-2023)
  • Table 190. Mexico Endocrinology Drugs Sales, by End User KG (2018-2023)
  • Table 191. Endocrinology Drugs: by Type(USD/Units)
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Endocrinology Drugs: by Type(USD Million)
  • Table 204. Endocrinology Drugs Diabetic Aagents , by Region USD Million (2025-2030)
  • Table 205. Endocrinology Drugs Hormone Agonists , by Region USD Million (2025-2030)
  • Table 206. Endocrinology Drugs Hormone Antagonists , by Region USD Million (2025-2030)
  • Table 207. Endocrinology Drugs: by Drug(USD Million)
  • Table 208. Endocrinology Drugs Prescription Drugs , by Region USD Million (2025-2030)
  • Table 209. Endocrinology Drugs Over-the-counter Drugs , by Region USD Million (2025-2030)
  • Table 210. Endocrinology Drugs: by End User(USD Million)
  • Table 211. Endocrinology Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 212. Endocrinology Drugs Commercial Laboratories , by Region USD Million (2025-2030)
  • Table 213. Endocrinology Drugs Ambulatory Care Centres , by Region USD Million (2025-2030)
  • Table 214. Endocrinology Drugs Others , by Region USD Million (2025-2030)
  • Table 215. South America Endocrinology Drugs, by Country USD Million (2025-2030)
  • Table 216. South America Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 217. South America Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 218. South America Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 219. Brazil Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 220. Brazil Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 221. Brazil Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 222. Argentina Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 223. Argentina Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 224. Argentina Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 225. Rest of South America Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 226. Rest of South America Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 227. Rest of South America Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 228. Asia Pacific Endocrinology Drugs, by Country USD Million (2025-2030)
  • Table 229. Asia Pacific Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 230. Asia Pacific Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 231. Asia Pacific Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 232. China Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 233. China Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 234. China Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 235. Japan Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 236. Japan Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 237. Japan Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 238. India Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 239. India Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 240. India Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 241. South Korea Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 242. South Korea Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 243. South Korea Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 244. Taiwan Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 245. Taiwan Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 246. Taiwan Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 247. Australia Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 248. Australia Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 249. Australia Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 250. Rest of Asia-Pacific Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 251. Rest of Asia-Pacific Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 252. Rest of Asia-Pacific Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 253. Europe Endocrinology Drugs, by Country USD Million (2025-2030)
  • Table 254. Europe Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 255. Europe Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 256. Europe Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 257. Germany Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 258. Germany Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 259. Germany Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 260. France Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 261. France Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 262. France Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 263. Italy Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 264. Italy Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 265. Italy Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 266. United Kingdom Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 267. United Kingdom Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 268. United Kingdom Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 269. Netherlands Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 270. Netherlands Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 271. Netherlands Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 272. Rest of Europe Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 273. Rest of Europe Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 274. Rest of Europe Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 275. MEA Endocrinology Drugs, by Country USD Million (2025-2030)
  • Table 276. MEA Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 277. MEA Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 278. MEA Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 279. Middle East Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 280. Middle East Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 281. Middle East Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 282. Africa Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 283. Africa Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 284. Africa Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 285. North America Endocrinology Drugs, by Country USD Million (2025-2030)
  • Table 286. North America Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 287. North America Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 288. North America Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 289. United States Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 290. United States Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 291. United States Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 292. Canada Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 293. Canada Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 294. Canada Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 295. Mexico Endocrinology Drugs, by Type USD Million (2025-2030)
  • Table 296. Mexico Endocrinology Drugs, by Drug USD Million (2025-2030)
  • Table 297. Mexico Endocrinology Drugs, by End User USD Million (2025-2030)
  • Table 298. Endocrinology Drugs Sales: by Type(KG)
  • Table 299. Endocrinology Drugs Sales Diabetic Aagents , by Region KG (2025-2030)
  • Table 300. Endocrinology Drugs Sales Hormone Agonists , by Region KG (2025-2030)
  • Table 301. Endocrinology Drugs Sales Hormone Antagonists , by Region KG (2025-2030)
  • Table 302. Endocrinology Drugs Sales: by Drug(KG)
  • Table 303. Endocrinology Drugs Sales Prescription Drugs , by Region KG (2025-2030)
  • Table 304. Endocrinology Drugs Sales Over-the-counter Drugs , by Region KG (2025-2030)
  • Table 305. Endocrinology Drugs Sales: by End User(KG)
  • Table 306. Endocrinology Drugs Sales Hospitals , by Region KG (2025-2030)
  • Table 307. Endocrinology Drugs Sales Commercial Laboratories , by Region KG (2025-2030)
  • Table 308. Endocrinology Drugs Sales Ambulatory Care Centres , by Region KG (2025-2030)
  • Table 309. Endocrinology Drugs Sales Others , by Region KG (2025-2030)
  • Table 310. South America Endocrinology Drugs Sales, by Country KG (2025-2030)
  • Table 311. South America Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 312. South America Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 313. South America Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 314. Brazil Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 315. Brazil Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 316. Brazil Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 317. Argentina Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 318. Argentina Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 319. Argentina Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 320. Rest of South America Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 321. Rest of South America Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 322. Rest of South America Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 323. Asia Pacific Endocrinology Drugs Sales, by Country KG (2025-2030)
  • Table 324. Asia Pacific Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 325. Asia Pacific Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 326. Asia Pacific Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 327. China Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 328. China Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 329. China Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 330. Japan Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 331. Japan Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 332. Japan Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 333. India Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 334. India Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 335. India Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 336. South Korea Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 337. South Korea Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 338. South Korea Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 339. Taiwan Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 340. Taiwan Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 341. Taiwan Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 342. Australia Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 343. Australia Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 344. Australia Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 345. Rest of Asia-Pacific Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 346. Rest of Asia-Pacific Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 347. Rest of Asia-Pacific Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 348. Europe Endocrinology Drugs Sales, by Country KG (2025-2030)
  • Table 349. Europe Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 350. Europe Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 351. Europe Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 352. Germany Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 353. Germany Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 354. Germany Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 355. France Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 356. France Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 357. France Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 358. Italy Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 359. Italy Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 360. Italy Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 361. United Kingdom Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 362. United Kingdom Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 363. United Kingdom Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 364. Netherlands Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 365. Netherlands Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 366. Netherlands Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 367. Rest of Europe Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 368. Rest of Europe Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 369. Rest of Europe Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 370. MEA Endocrinology Drugs Sales, by Country KG (2025-2030)
  • Table 371. MEA Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 372. MEA Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 373. MEA Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 374. Middle East Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 375. Middle East Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 376. Middle East Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 377. Africa Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 378. Africa Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 379. Africa Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 380. North America Endocrinology Drugs Sales, by Country KG (2025-2030)
  • Table 381. North America Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 382. North America Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 383. North America Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 384. United States Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 385. United States Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 386. United States Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 387. Canada Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 388. Canada Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 389. Canada Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 390. Mexico Endocrinology Drugs Sales, by Type KG (2025-2030)
  • Table 391. Mexico Endocrinology Drugs Sales, by Drug KG (2025-2030)
  • Table 392. Mexico Endocrinology Drugs Sales, by End User KG (2025-2030)
  • Table 393. Endocrinology Drugs: by Type(USD/Units)
  • Table 394. Research Programs/Design for This Report
  • Table 395. Key Data Information from Secondary Sources
  • Table 396. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Endocrinology Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Endocrinology Drugs: by Drug USD Million (2018-2023)
  • Figure 6. Global Endocrinology Drugs: by End User USD Million (2018-2023)
  • Figure 7. South America Endocrinology Drugs Share (%), by Country
  • Figure 8. Asia Pacific Endocrinology Drugs Share (%), by Country
  • Figure 9. Europe Endocrinology Drugs Share (%), by Country
  • Figure 10. MEA Endocrinology Drugs Share (%), by Country
  • Figure 11. North America Endocrinology Drugs Share (%), by Country
  • Figure 12. Global Endocrinology Drugs: by Type KG (2018-2023)
  • Figure 13. Global Endocrinology Drugs: by Drug KG (2018-2023)
  • Figure 14. Global Endocrinology Drugs: by End User KG (2018-2023)
  • Figure 15. South America Endocrinology Drugs Share (%), by Country
  • Figure 16. Asia Pacific Endocrinology Drugs Share (%), by Country
  • Figure 17. Europe Endocrinology Drugs Share (%), by Country
  • Figure 18. MEA Endocrinology Drugs Share (%), by Country
  • Figure 19. North America Endocrinology Drugs Share (%), by Country
  • Figure 20. Global Endocrinology Drugs: by Type USD/Units (2018-2023)
  • Figure 21. Global Endocrinology Drugs share by Players 2023 (%)
  • Figure 22. Global Endocrinology Drugs share by Players (Top 3) 2023(%)
  • Figure 23. Global Endocrinology Drugs share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 26. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 27. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2023
  • Figure 31. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 33. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Eli Lily (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lily (United States) Revenue: by Geography 2023
  • Figure 37. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 39. HanAll BioPharma (South Korea) Revenue, Net Income and Gross profit
  • Figure 40. HanAll BioPharma (South Korea) Revenue: by Geography 2023
  • Figure 41. Bayer HealthCare Pharmaceuticals (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Bayer HealthCare Pharmaceuticals (Germany) Revenue: by Geography 2023
  • Figure 43. Acerus Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 44. Acerus Pharmaceuticals (Canada) Revenue: by Geography 2023
  • Figure 45. BHV Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 46. BHV Pharma (United States) Revenue: by Geography 2023
  • Figure 47. Global Endocrinology Drugs: by Type USD Million (2025-2030)
  • Figure 48. Global Endocrinology Drugs: by Drug USD Million (2025-2030)
  • Figure 49. Global Endocrinology Drugs: by End User USD Million (2025-2030)
  • Figure 50. South America Endocrinology Drugs Share (%), by Country
  • Figure 51. Asia Pacific Endocrinology Drugs Share (%), by Country
  • Figure 52. Europe Endocrinology Drugs Share (%), by Country
  • Figure 53. MEA Endocrinology Drugs Share (%), by Country
  • Figure 54. North America Endocrinology Drugs Share (%), by Country
  • Figure 55. Global Endocrinology Drugs: by Type KG (2025-2030)
  • Figure 56. Global Endocrinology Drugs: by Drug KG (2025-2030)
  • Figure 57. Global Endocrinology Drugs: by End User KG (2025-2030)
  • Figure 58. South America Endocrinology Drugs Share (%), by Country
  • Figure 59. Asia Pacific Endocrinology Drugs Share (%), by Country
  • Figure 60. Europe Endocrinology Drugs Share (%), by Country
  • Figure 61. MEA Endocrinology Drugs Share (%), by Country
  • Figure 62. North America Endocrinology Drugs Share (%), by Country
  • Figure 63. Global Endocrinology Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Novo Nordisk (Denmark)
  • Merck & Co., Inc. (United States)
  • Sanofi (France)
  • AstraZeneca plc (United Kingdom)
  • GlaxoSmithKline plc (United Kingdom)
  • Eli Lily (United States)
  • AbbVie Inc. (United States)
  • HanAll BioPharma (South Korea)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Acerus Pharmaceuticals (Canada)
  • BHV Pharma (United States)
Additional players considered in the study are as follows:
Acrux DDS (Australia) , Biocon (India) , Hanmi Pharmaceutical (South Korea) , MannKind (United States) , Precigen, Inc (United States) , ChipScreen Biosciences (China) , Endo Pharmaceuticals (Ireland) , Takeda Pharmaceuticals (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 202 Pages 88 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Endocrinology Drugs Quantitative research analysis
Global Endocrinology Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novo Nordisk (Denmark), Merck & Co., Inc. (United States), Sanofi (France), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Eli Lily (United States), AbbVie Inc. (United States), HanAll BioPharma (South Korea), Bayer HealthCare Pharmaceuticals (Germany), Acerus Pharmaceuticals (Canada) and BHV Pharma (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"High Prevalence of Diabetes" is seen as one of major influencing trends for Endocrinology Drugs Market during projected period 2023-2030.
The Endocrinology Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Endocrinology Drugs Report?

Have a Query? Click Here

Other Related Reports

Cancer Supportive Care Products Comprehensive Study by Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others), Distrib...
$ 3750
Bulk Drug Comprehensive Study by Type (Branded Prescription Drugs, Over-The-Counter Drugs, Generic Prescription Drugs), Application (Pharmaceutical, Healthcare), Processing Stages (Primary Processing...
$ 3750
Hemorrhagic Septicemia Vaccines Comprehensive Study by Type (Oil - Adjuvant, Aluminium Hydroxide- Adjuvant), Application (Cattle, Buffaloes), End User (Veterinary Hospitals, Veterinary Clinics, Anima...
$ 3500
Immunosuppressant Drugs Comprehensive Study by End-users (Hospitals, Clinics, Others), Indication (Organ Transplantation, Autoimmune Disorders, Non-autoimmune Inflammatory Diseases), Distribution Cha...
$ 3750
Rupatadine Comprehensive Study by Type (150 mg Tablets, 300 mg Tablets, Others), Application (Allergic Rhinitis, Urticaria), Dosage (Tablets, Capsules, Syrup), End User (Hospitals, Clinics) Players a...
$ 3500
Pharma Ophthalmic Comprehensive Study by Type (Prescription Drugs, Over-the-Counter Drugs), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Independent Pharmacies & Drug Stores), Therap...
$ 3750